144 related articles for article (PubMed ID: 38536543)
1. Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer.
Hori T; Yamamoto K; Ito T; Ikushima S; Omura T; Yano I
Invest New Drugs; 2024 Jun; 42(3):281-288. PubMed ID: 38536543
[TBL] [Abstract][Full Text] [Related]
2. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
3. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
[TBL] [Abstract][Full Text] [Related]
4. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
[TBL] [Abstract][Full Text] [Related]
5. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
[TBL] [Abstract][Full Text] [Related]
8. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
Wang X; Cai J; Zeng Z; Liu A
BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
[TBL] [Abstract][Full Text] [Related]
10. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
12. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
[TBL] [Abstract][Full Text] [Related]
13. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
[TBL] [Abstract][Full Text] [Related]
14. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang YK; Cobo M; Kasahara K; Cheng Y; Nogami N; Cho EK; Su WC; Zhang G; Huang X; Li-Sucholeiki X; Lentrichia B; Dearden S; Jenkins S; Saggese M; Rukazenkov Y; Ramalingam SS
Clin Cancer Res; 2019 Nov; 25(22):6644-6652. PubMed ID: 31439584
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M;
Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Nakashima K; Ozawa Y; Daga H; Imai H; Tamiya M; Tokito T; Kawamura T; Akamatsu H; Tsuboguchi Y; Takahashi T; Yamamoto N; Mori K; Murakami H
Invest New Drugs; 2020 Dec; 38(6):1854-1861. PubMed ID: 32424780
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
Yi L; Fan J; Qian R; Luo P; Zhang J
Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH; Lim SH; An HJ; Kim KH; Park KU; Kang EJ; Choi YH; Ahn MS; Lee MH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
J Clin Oncol; 2020 Feb; 38(5):488-495. PubMed ID: 31825714
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib in Resected
Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
